-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our 12-month price target to $860 from $1,080, 19.4x our FY 27 EPS estimate (up $0.11 to $44.24; FY 28 estimate begins at $50.19), a above peers and MCK's three-year forward average of 18.6x, supported by a stronger margin profile and faster near-term EPS and dividend growth expectations within a favorable environment for pharma distributors, in our view. Looking ahead to FY 27, we expect broad-based growth across core pharma distribution, oncology and multispecialty, and Rx Technology, with more modest growth in Medical-Surgical, supporting overall sales growth near 7%, following 12% growth in FY 26. We attribute the sales growth slowdown to difficult comparisons as well as lower branded drug pricing as certain Inflation Reduction Act provisions take effect. Oncology and multispecialty should produce the strongest profitability growth during FY 27, in our view, followed by the Rx Technology business and core pharma distribution, driving overall adjusted EBIT growth near 9%.